TRACON Pharmaceuticals In... (TCON)
0.03
-0.00 (-6.83%)
At close: Feb 28, 2025, 3:00 PM
1.08
3254.04%
After-hours: Jun 27, 2024, 07:53 PM EDT
No 1D chart data available
| Bid | 1.05 |
| Market Cap | 109.72K |
| Revenue (ttm) | 3.63M |
| Net Income (ttm) | 5.88M |
| EPS (ttm) | 5.93 |
| PE Ratio (ttm) | 0.01 |
| Forward PE | -0.17 |
| Analyst | n/a |
| Ask | 1.08 |
| Volume | 15,047 |
| Avg. Volume (20D) | 102,280.516 |
| Open | 0.04 |
| Previous Close | 0.03 |
| Day's Range | 0.03 - 0.04 |
| 52-Week Range | 0.00 - 14.75 |
| Beta | 1.42 |
About TCON
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 30, 2015
Employees 17
Stock Exchange NASDAQ
Ticker Symbol TCON
Website https://www.traconpharma.com
9 months ago
-17.77%
TRACON Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
11 months ago
-24.85%
TRACON Pharmaceuticals shares are trading lower after the company announced a 1-for-20 reverse stock split.
9 months ago · seekingalpha.com
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call TranscriptTRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Charles Theuer - President & CEO Scott Brown - CFO Conference Call Participant...
